Obatoclax mesilate

Obatoclax (803712-79-0) is a novel Bcl-2 homology domain-3 (BH3) mimetic.1?Inhibits primary acute myeloid leukemia (AML) progenitor cell proliferation (IC50=0.18 μM) and induces apoptosis in primary AML cells (IC50= 3.6 μM).2?Obatoclax synergizes with other agents such as chloroquine3?and cytarabine4?in cytotoxicity against a variety of cancer cells.

Red powder

Obatoclax (GX15-070) is an inhibitor of Bcl-2 with Ki of 0.22 μM.

Obatoclax Mesylate is a novel Bcl-2 homology domain-3 (BH3) mimetic.

Store at -20°C

1) Chonghaile and Letai (2008),?Mimicking the BH3 domain to kill cancer cells; Oncogene,?27?S149 2) Konopleva?et al. (2008),?Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax); Cancer Res.,?68?3413 3) Wang?et al. (2014),?Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells; Oncol. Rep.,?32?2789 4) Xie?et al. (2015),?Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage; Mol. Oncol.,?9?409